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Bacille Calmette–Gue´rin (BCG) immunization provides variable protection
against tuberculosis. Prenatal antigen exposure may have lifelong effects on
responses to related antigens and pathogens. We therefore hypothesized that
maternal latent Mycobacterium tuberculosis infection (LTBI) influences infant
responses to BCG immunization at birth. We measured antibody (n ¼ 53)
and cellular (n ¼ 31) responses to M. tuberculosis purified protein derivative
(PPD) in infants of mothers with and without LTBI, in cord blood and at one
and six weeks after BCG. The concentrations of PPD-specific antibodies
declined between birth (median [interquartile range (IQR)]) 5600 ng ml21
[3300–11 050] in cord blood) and sixweeks (0.00 ng ml21 [0–288]). Frequencies
of PPD-specific IFN-g-expressing CD4þT cells increased at one week and
declined between one and six weeks ( p ¼ 0.031). Frequencies of IL-2-
and TNF-a-expressing PPD-specific CD4þT cells increased between one and
six weeks (p ¼ 0.019, p ¼ 0.009, respectively). At one week, the frequency of
PPD-specific CD4þT cells expressing any of the three cytokines, combined,
was lower among infants of mothers with LTBI, in crude analyses
(p ¼ 0.002) and after adjusting for confounders (mean difference, 95% CI
20.041% (20.082, 20.001)). In conclusion, maternal LTBI was associated
with lower infant anti-mycobacterial T-cell responses immediately following
BCG immunization. These findings are being explored further in a larger study.
1. Introduction
Bacille Calmette–Gue´rin (BCG) is the only vaccine against tuberculosis (TB)
currently available, but its protective efficacy varies between populations.
Meta-analyses of trials of BCG immunization have shown that latitude is an
important factor in the protection achieved in adolescents and adults [1–3].
This is an observation of great public health concern, since TB is a major
cause of morbidity and mortality in developing tropical countries, where its
endemicity is very high [4].
One hypothesis that has been advanced to explain the variability in BCG
efficacy, and its relationship to latitude, is that sensitization to non-tuberculous
mycobacteria (NTM), which is more common in lower latitudes [5], modifies
the protection induced by BCG [6]. Exposure to NTMmight block the induction
of a protective effect by BCG, or might provide equivalent protection to BCG,
obscuring the benefit provided by BCG. However, the hypothesis that exposure
to NTM confers protection does not seem consistent with the high incidence of
& 2015 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
 on July 29, 2015http://rstb.royalsocietypublishing.org/Downloaded from 
TB in tropical countries. It is recommended for BCG to be
given at birth in low income settings [7]. In Uganda, hospi-
tal-born infants are immunized within hours of birth,
before discharge [8]. In studies where BCG is administered
early in life, BCG induces strikingly different profiles of
immune response in Africa compared with the UK [9].
For infants immunized some months after birth, prior sen-
sitization has been attributed to early exposure to
environmental mycobacteria [10]. This is likely to contribute,
but we postulate that intrauterine exposures may result in a
more significant modification in the profile of response
(which may indeed be reflected in the response to subsequent
exposure to environmental mycobacteria, to BCG, or to TB).
Latent Mycobacterium tuberculosis infection (LTBI) is
thought to involve a dynamic relationship between myco-
bacteria and the immune system. Individuals with LTBI
may have circulating antigen and higher concentrations of
TB-specific antibodies than those without infection. Myco-
bacterial antigens have been found to cross the placenta in
murine models [11]. Thus, maternal LTBI might lead to
exposure to mycobacterial antigens in utero and the develop-
ment of a modified profile of sensitization [12], or the
induction of tolerance [13,14] in the fetus. Alternatively, the
passive transfer of maternal anti-mycobacterial antibodies,
by providing passive immunity, might interfere with the abil-
ity of the BCG vaccine to elicit protective cellular responses.
Maternal LTBI could also influence the maternal and placen-
tal immunological milieu, and hence the fetal and neonatal
response on exposure to immunization [15].
We therefore propose the hypothesis that maternal LTBI
influences the neonatal response to BCG (and toM. tuberculosis),
rendering the response to BCG less effective and susceptibility
to TB greater.
In Uganda, where the annual incidence of tuberculous
infection is estimated at 3%, up to 60% of young women of
childbearing age are likely to be infected. We present results
of a pilot study to investigate the progression of immune
responses to mycobacterial antigen, and the relationship
between maternal infection with M. tuberculosis and infant
immune responses, following BCG immunization at birth.
2. Material and methods
(a) Study design and setting
We investigated healthy infants ofmothers with andwithout LTBI.
Women residing within the study area (Entebbe Municipality and
Katabi sub-county, Wakiso district, Uganda) and delivering in
Entebbe General Hospital were eligible for inclusion. Pregnant
womenwere given prior information about the study during ante-
natal visits. On admission in early labour they were approached
for consent if they were willing to participate in the study, had a
normal singleton pregnancy and were HIV negative (based on
antenatal records). Following consent, cord blood was obtained
at delivery. After delivery, a brief questionnaire was completed
and BCG immunization was given to the neonates before
discharge from hospital. A single batch of the BCG vaccine,
BCG-Russia (BCG-1 Moscow strain, Serum Institute of India,
India) was used. BCG was administered intradermally for all
infants within 48 h of birth.
Neonates were excluded if cord blood was not obtained, the
delivery was complicated, birth weight was below 2500 g, or if
the neonate presented with significant congenital abnormalities
or was clinically unwell, as judged by the midwife.
Motherswere asked to return to the clinic oneweek after deliv-
ery. At this time, a maternal blood sample was obtained for
investigation of LTBI by T-SPOT.TB assay (Oxford Immunotec,
Abingdon, UK) and a tuberculin skin test (TST; 2 tuberculin
units, Statens Serum Institut, Copenhagen, Denmark) was per-
formed. This was read between 48 and 72 h later and was
defined as positive if greater than or equal to 10 mm in diameter.
Mothers were regarded as LTBI-positive if both T-SPOT.TB and
TST were positive, and LTBI-negative if both were negative.
A positive response to ESAT-6 and CFP-10 in the T-SPOT.TB was
considered likely to represent M. tuberculosis infection in this set-
ting, although a small number of other mycobacterial species do
express these antigens [16–19].
A repeat HIV test was also performed using the standard rapid
test algorithm (usually Determine (Inverness Medical, Tokyo,
Japan) confirmed by HIV 1/2 STAT-PAK Dipstick test (Chembio
Diagnostic Systems, Medford, NY, USA) with Uni-Gold HIV test
(Trinity Biotech plc, Bray, Ireland) as a tie-breaker). Mothers with
LTBI were investigated for active TB based on symptoms,
sputum examination (if available) and chest X-ray. Mother–baby
pairs were excluded if T-SPOT.TB and TST results were discordant
or if the mother was found to be HIV-positive.
Peripheral venous blood was obtained from each infant at one
and six weeks after BCG immunization. The number of infants
included in this pilot study was chosen to be feasible within the
time frame and resources available, and analyses were restricted
to infants who had relevant results at all time points.
(b) ELISA for anti-PPD and anti-tetanus toxoid total IgG
antibodies
Total plasma immunoglobulin(Ig)G specific for PPD and tetanus
toxoid (TT) was assayed using an ‘in-house’ indirect enzyme-
linked immunosorbent assay (ELISA). Briefly, flat-bottomed
96-well Microlon plates (Greiner Bio-one, Germany) were coated
with purified IgG standard (GenScript, NJ, USA) in bicarbonate
coating buffer at maximum concentration of 0.625 mg ml21 and
minimum concentration of 0.01 mg ml21, and PPD (10 mg ml21,
RT 50, Statens Serum Institut, Copenhagen, Denmark) or TT
(12.12 Lf/ml, T155-1, Statens Serum Institut, Copenhagen,
Denmark). Each PPD and TT well had a control comprising 0.1%
Marvel milk powder (Premier International Foods, UK) in coating
buffer. After overnight incubation, the plates were blocked with
150 ml well21 of 1%milk powder/PBS for 1 h at room temperature.
Samples diluted 1 in 100 in 0.1% milk powder/PBS were added
to the plates and left overnight at 48C. Polyclonal anti-human
IgG horseradish peroxidase (Poly HRP, 0.5 mg ml21, Dako,
Denmark) was added at 50 ml well21 and plates incubated for 1 h
at room temperature. A total of 100 ml well21 of o-phenylene-
diamine (OPD, Sigma-Aldrich, MO, USA) substrate mixture
(3 mg OPD, 0.1 M citric acid, 0.2 M Na2HPO4, 3 ml 30% hydrogen
peroxide in distilledwater) was added for 15 min at room tempera-
ture (in the dark). The reaction was stopped with 25 ml well21 2 M
sulfuric acid and the plates were read at test wavelength 490 nm
and reference wavelength 630 nm using an MRX1.1 plate reader
and GEN5 1.07 software (BioTek Instruments, Inc., VT, USA). The
sensitivity of the test was determined as the lowest standard con-
centration above which antibody concentrations were detectable
(0.01 mg ml21).
(c) Separation of mononuclear cells
Mononuclear cells were isolated from cord blood, and from infant
blood obtained at one and six weeks after birth, by standard
Ficoll-Paque (Sigma-Aldrich) density gradient centrifugation, and
cryopreserved in 50% fetal calf serum (FCS) (Sigma-Aldrich), 40%
RPMI 1640medium (Life Technologies Corporation, NY, USA) con-
taining 2 mM L-glutamine, 100 U ml21 penicillin G, 100 mg ml21
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streptomycin sulfate and HEPES and 10% dimethylsulfoxide
(DMSO) (Sigma-Aldrich) according to standard protocols.
(d) Intracellular cytokine staining assay
The cells were thawed and rested for 24 h at 378C in 5%CO2, viabi-
lity and numbers were checked using Cellometer Vision Cell
Profiler (Nexcelom Bioscience, LLC-Lawrence, MA, USA), and
cells were stimulated with M. tuberculosis-purified protein
derivative (PPD, 20 mg ml21, RT 50, Statens Serum Institut,
Copenhagen, Denmark). Medium alone was used as a negative
control, and staphylococcal enterotoxin B (SEB, 200 ng ml21,
Sigma-Aldrich) served as a positive control. The co-stimulatory
antibodies anti-CD28 and anti-CD49d (1 mg ml21, BD Biosciences,
San Jose, CA, USA) were included in all conditions. The cells were
incubated at 378C in 5% CO2 for a total of 24 h. Brefeldin A
(10 mg ml21, Sigma-Aldrich) was added to SEB wells after 2 h,
and to PPD and negative control wells after 20 h. The cells were
then stained with aqua viability dye (Life Technologies, OR,
USA), and antibodies directed against the following human mol-
ecules: CD3 (QDot655, S4.1) and CD4 (QDot605, S3.50), both
obtained from Life Technologies, OR, USA; CD8 (BV570, RPA-
T8, BioLegend, San Diego, CA, USA); and IFN-g (APC, B27),
TNF-a (PE-Cy7, Mab11) and IL-2 (FITC, 5344.111), all obtained
from BD Biosciences, NJ, USA. Stained cells were acquired on an
LSRII flow cytometer (BD Biosciences, NJ, USA). Flow cytometry
was not performed blinded to the maternal LTBI status, but the
infants’ samples were tested in a randomized sequence to limit
the possibility of bias in the results due to day-to-day variation
in the assay.
(e) Statistical analysis
Antibody concentrations were summarized using medians and
interquartile ranges (IQR) and compared between different time
points using paired t-test. Antibody levels showed a skewed distri-
bution with large numbers of undetectable results, therefore
results were transformed to log10 (antibody concentration þ 1)
for graphical presentation. Flow cytometry data were analysed
using FLOWJO v. 9.5.2 (Tree Star Inc., Ashland, OR, USA). Results
were expressed as the frequency of positive events above the nega-
tive control. PRISM v6.0e (GraphPad software, Inc., La Jolla, CA,
USA) was used for crude analyses and data presentation. Charac-
teristics of mothers with and without LTBI were compared using
the Mann–Whitney U-test. Responses at different time points
were compared using the Wilcoxon signed-rank test. Differences
in responses between LTBI exposed and unexposed infants were
analysed using the Mann–Whitney test. STATA v. 13.0 (College
Station, TX, USA) was used for multivariable linear regression to
adjust for potential confounders (maternal age, gravidity status
and infant gender), with 95% confidence intervals (CI) estimated
by bootstrapping. Only three mothers had helminth infections
and therefore this was not included as potential confounder.
Results from regression analyses were presented as crude and
adjusted mean difference (95% CI). p-Values of less than 0.05
were considered statistically significant.
3. Results
(a) Participant characteristics
Between February and May 2012, 175 women were
approached to participate and 145 were enrolled in the study
(figure 1). Fifty-one enrolled mothers were excluded, in most
cases because contact details were not taken and they could
not be traced when they defaulted from further follow-up.
The remaining 94 mothers were tested for LTBI. Of these 23
were excluded, in most cases for discordant LTBI results.
Twenty-one mothers were identified as LTBI-positive and
50 as LTBI-negative. None of the mothers was found to be
infected with HIV on repeat testing.
Mothers with LTBI, compared to thosewithout, were older
(mean age 27.5 versus 23 years, p ¼ 0.002), less likely to be pri-
migravida (32% versus 48%, p, 0.001) and less likely to have a
BCG scar (47% versus 70%, p, 0.001), and their children were
more likely to be male (53% versus 35%, p, 0.001).
(b) Longitudinal changes in IgG concentration
Plasma samples obtained from cord blood and infant samples
collected at one and six weeks after neonatal BCG immuniz-
ation were analysed for IgG specific for PPD and TT using
ELISA. The main outcome of interest was the IgG response to
PPD. TT-specific antibodies were assayed for comparison.
Fifty-three samples were assayed at each time point, 15 from
infants of mothers with LTBI and 38 from infants of mothers
without LTBI. The distribution of concentrations of IgG speci-
fic for PPD and TT in the three sample types is illustrated in
figure 2. Compared to the concentration in cord blood
(median [IQR]: 5600 ng ml21 [3300–11 050]), PPD-specific
IgG concentrations decreased at one week after birth
(175 ng ml21 [0–1100], p, 0.001) and again at six weeks
(0.00 ng ml21 [0.00–288], p ¼ 0.004; figure 2a).
By contrast, the concentration of TT-specific IgG was high
in cord blood (46 750 ng ml21 [42 000–49 950], dropped
less dramatically by one week after birth (21 125 ng ml21
[18 988–22 650] p, 0.001) and showed little change bet-
ween one and six weeks (19 550 ng ml21 [13 750–22 038]
p ¼ 0.252; figure 2b).
(c) Longitudinal changes in frequencies of PPD-specific
CD4þ and CD8þ T cells
The frequency of CD4þ T cells expressing a PPD-specific
IFN-g response increased at one week and decreased at six
weeks after birth, compared to responses in cord blood.
The difference between frequencies at one and six weeks
was statistically significant ( p ¼ 0.031). By contrast, the fre-
quencies of cells expressing IL-2 and TNF-a were higher at
six weeks compared to one week ( p ¼ 0.018 and p ¼ 0.009,
respectively; figure 3a).
The frequency of PPD-specific CD8þ T cells making any
of the three cytokines assessed decreased at six weeks com-
pared with one week ( p ¼ 0.003), and six weeks compared
with cord blood ( p ¼ 0.044; figure 3b).
There was no correlation between PPD IgG concentrations
and frequencies of cytokine-expressing cells in cord blood, or
at one and six weeks (data not shown).
(d) Impact of maternal infection with Mycobacterium
tuberculosis on PPD-specific immune responses
in infancy
Cordblood samples obtained from infants ofmotherswithLTBI,
compared to thosewithout LTBI, showed aweak trend towards
higher T-cell responses (p¼ 0.48 for IFN-g (figure 4a), p¼ 0.20
for IL-2 (figure 4b), p ¼ 0.27 for TNF-a (figure 4c), p¼ 0.40
for all cytokines, combined (figure 4d)). There was a similar,
weak trend in cord blood PPD-specific IgG concentration (data
not shown).
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At one week after BCG immunization, in univariable ana-
lyses, maternal LTBI was associated with lower frequencies
of CD4þ T cells expressing PPD-specific IFN-g ( p ¼ 0.015,
figure 4a) and of CD4þ T cells expressing any of the three
cytokines assessed, combined ( p ¼ 0.002, figure 4d ).
The mean number of cells acquired was 38 000, but 12 of
the 93 samples analysed had less than 5000 events acquired.
These samples came from seven infants. When affected
infants were excluded from the analysis, the association
between maternal LTBI and lower frequencies of CD4þ T
cells expressing PPD-specific IFN-g at age one week was
weakened ( p ¼ 0.068), but that of TNF-a was strengthened
( p ¼ 0.045) (data not shown). Overall, the evidence for an
association between maternal LTBI and infant T helper 1
(Th1) responses was therefore maintained.
In multivariable analyses incorporating all samples, after
adjusting for maternal age, maternal gravidity and infant
gender, the association between maternal LTBI and frequen-
cies of IFN-g-expressing cells was weaker than in the crude
analysis (mean difference (95% confidence interval (CI))
20.026% (20.071, 0.019), but the association with a reduced
frequency of TNF-a-expressing CD4þ T cells was stronger
(20.012% (20.021, 20.003)), and the association between
maternal LTBI and reduced frequencies of PPD-specific
CD4þ T cells expressing any of the three cytokines, combined,
remained strong (adjusted mean difference, 95% CI 20.041%
(20.082, 20.001)).
For CD8þ T cells, there was a similar, weak, association
between maternal LTBI and low frequencies of PPD-specific
T cells at one week (adjusted mean difference, 95% CI 20.019
(20.042, 0.004)). There were no other differences in CD8þ
T-cell responses between mothers with and without LTBI.
4. Discussion
In this study, the course of immune responses to mycobacterial
antigen was studied in cord blood and in infants at one and six
weeks after neonatal BCG immunization, and the effect of
maternal infection with M. tuberculosis on the infant immune
response following neonatal BCG immunization was investi-
gated. The immune response was measured by PPD-specific
approached for consent
(n = 175)
excluded (n = 30)
— lives outside study area (n = 3)
— did not consent (n = 24)
— complicated labour (n = 1)
— language barrier (n = 2)
enrolled
(n = 145)
discontinued (n = 51)
— cord blood not collected (n = 5)
— baby underweight (n = 3)
— address not taken (n = 40)
— sickness (n = 2)
— changed address (n = 1)
infected
(n = 21)
tested for latent
tuberculosis infection
(n = 94)
uninfected
(n = 50)
discontinued (n = 23)
— discordant results (n = 20)
— indeterminate results (n = 1)
— sickness (n = 2)
completed follow up
(n = 17)
completed follow up
(n = 40)
Figure 1. Flow of participants through the study.
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plasma immunoglobulin-G concentration and frequencies
of PPD-specific T cells. Two key observations emerged.
First, mycobacteria-specific antibody concentrations dropped
rapidly in the first six weeks of life. Second, maternal infection
with M. tuberculosis was associated with lower infant T-cell
responses one week after BCG immunization.
IgG is transferred from the mother across the placenta to
the fetus by use of the neonatal Fc receptor (FcRn) [20]. Levels
of passively transferred antibody to some organisms can
remain high for months [21–23]. We predicted that there
would be differences in concentrations of passively trans-
ferred PPD-specific antibody between infants of mothers
with and without LTBI and that these differences would be
sustained to at least six weeks of age. Added to this, there
is evidence that BCG induces an antibody response [24] so
infant antibody levels might be supplemented by those
derived from the infant’s own cells, post-BCG. It was there-
fore surprising to find that infant PPD-specific antibody
concentrations dropped so markedly at one week after BCG
immunization, with a further drop at six weeks such that
the median response was then effectively zero. By contrast,
there was only a gradual decay in maternally derived TT-
specific antibodies. We speculate that the PPD-specific anti-
bodies were lost from circulation by binding to the BCG
vaccine, or to antigens released by the bacteria, and that
this may affect the efficacy of the BCG vaccine. It will be
important to further understand this phenomenon and to
confirm its influence on BCG immunization during infancy.
A randomized comparison of delayed versus immediate
BCG immunization would present an opportunity to deter-
mine whether neonatal BCG immunization causes the
immediate decline of passively transferred antibody and to
explore these effects.
The median PPD-specific antibody concentrations in the
infants of mothers with LTBI showed a tendency to be
higher than for infants of mothers without LTBI. This was
consistent with our hypothesis, although not statistically sig-
nificant, and a larger study is needed to explore this further.
If found to be significant, this would provide one possible
mechanism for a difference in response to BCG immunization
between infants of mothers with and without LTBI.
We report mycobacteria-specific T-cell responses follow-
ing BCG immunization that are of comparable, but often
lower, magnitude than those reported by Soares et al. [25].
In our study, the frequency of PPD-specific IFN-g-expressing
CD4þ T cells was highest one week after BCG immunization
and decreased at six weeks, while the frequencies of PPD-
specific IL-2 and TNF-a-expressing CD4þ T cells increased
at six weeks. Soares et al. [25] have previously reported a
peak in BCG-specific T-cell responses for each of these cyto-
kines at 6–10 weeks after immunization. Our follow-up
was too short to allow detection of a later peak. Our study
differed from that of Soares et al. in other important respects.
For example, our infants received BCG-Russia strain (Serum
Institute of India, India), while Soares and colleagues pro-
vided Danish strain 1331 (Statens Serum Institut). We, and
others, have shown that different BCG strains induce differ-
ent responses and, in particular, that BCG-Russia induces
lower initial responses than BCG Danish [26,27]. Also, we
used frozen mononuclear cells (which may have resulted in
lower responses compared to Soares et al., who used fresh
whole blood [28]), stimulated cells for 24 h with PPD rather
than for 12 h with BCG, and added brefeldin A at 20 h,
compared with 7 h for Soares et al.
PPD-specific T-cell responses in cord blood tended to be
higher in infants of mothers with LTBI than those born of
mothers without LTBI. Although these differences were not
statistically significant, they were consistent with previous
studies demonstrating in utero sensitization to PPD among
infants from mothers residing in a TB-endemic setting [12].
We found that maternal infection with M. tuberculosis
was associated with lower infant PPD-specific CD4þ T-cell
responses one week after neonatal BCG immunization,
especially when the results for all three measured Th1 cyto-
kines were combined. This is an observation of potential
public health significance since policy in most tropical
countries is for the BCG vaccine to be given at birth, and
LTBI is common in these settings. The association was only
seen at this early time point, and the implications of this
for longer term, protective immunity are not clear. By con-
trast, in a recent study, Jones et al. [29] reported no
difference in BCG-specific responses between infants exposed
or unexposed to maternal M. tuberculosis. Again, there were
important differences between our study and that of Jones
and colleagues. These include the definition of maternal
LTBI (both TST and T-SPOT.TB positive in our study,
versus the less stringent QuantiFERON-TB Gold test positive,
only, in Jones’s study: the broader definition by Jones et al.
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may have contributed to smaller differences between their
LTBI categories). There were differences in BCG strains
used (again, Jones et al. used Danish strain 1331, versus
BCG-Russia). Again, the schedules of the studies differed:
Jones et al. immunized their infants at six weeks of age
(rather than at birth) and first assessed responses 10 weeks
later (potentially missing a transient early effect, such as we
observed). There were also differences in the assays used:
Jones et al. used a 6-day whole blood assay, whereas we
used a 24-h mononuclear cell stimulation assay.
There are currently no known correlates of protection
against TB. The results from this study therefore have to be
interpreted with caution. However, if our pilot results are cor-
rect, and reflect a true difference in immune response to BCG
immunization between infants of mothers with and without
LTBI, there may be a need to investigate the effects of treating
LTBI in women of childbearing age in endemic countries on
the outcome of BCG immunization in their infants.
The sample size for this pilot study was small, and many
outcomes were analysed, hence it is possible that some of
0.25
0.20
0.15
0.10
0.05
–0.05
0.08
0.06
0.04
0.02
–0.02
0.25
0.20
0.15
0.10
0.05
–0.05
0
0.25
0.20
0.15
0.10
0.05
–0.05
0
0
0
LTBI unexposed LTBI exposed LTBI unexposed LTBI exposed
cord blood one week post-BCG
IF
N
-g
+
 C
D
4+
 
T 
ce
lls
 (%
)
IL
-2
+
 C
D
4+
 
T 
ce
lls
 (%
)
TN
F-
a+
 C
D
4+
 
T 
ce
lls
 (%
)
to
ta
l c
yt
ok
in
e+
 C
D
4+
T 
ce
lls
 (%
)
p = 0.478 p = 0.015
p = 0.199 p = 0.958
p = 0.268
p = 0.397 p = 0.977
(b)
(a)
(c)
(d )
six weeks post-BCG
p = 0.415
p = 0.698
p = 0.133 p = 0.441
LTBI unexposed LTBI exposed
LTBI unexposed LTBI exposed LTBI unexposed LTBI exposedLTBI unexposed LTBI exposed
LTBI unexposed LTBI exposed LTBI unexposed LTBI exposedLTBI unexposed LTBI exposed
LTBI unexposed LTBI exposed LTBI unexposed LTBI exposedLTBI unexposed LTBI exposed
p = 0.002
Figure 4. The effect of maternal LTBI on frequencies of PPD-specific CD4þ T cells. Frequencies for PPD-specific IFN-gþ (a), IL-2þ (b), TNF-aþ (c) and for all three
cytokines combined (total cytokineþ (d )) cells in cord blood and infant samples obtained at one and six weeks, comparing infants unexposed and exposed to
maternal latent M. tuberculosis. Each symbol represents an individual, and for each plot the horizontal line represents the median. Statistical analysis was performed
using Mann–Whitney test; n ¼ 17 for infants of mothers without LTBI and 14 for infants of mothers with LTBI.
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our findings could be a consequence of multiple testing.
Therefore, our initial results need to be explored further in
studies with a larger sample size, and this must also be suffi-
cient to allow adjustment for potential confounders for effects
of LTBI. Early, as well as longer term, time points must be
included. Small blood volumes were obtained from these
infants and these yielded low cell numbers. Low frequencies
of mycobacteria-specific T cells imply the need to acquire
reasonably large numbers of cells during flow cytometry,
and fresh whole blood, processed quickly, is likely to be
more informative than frozen cells [28].
In conclusion, our results suggest that mycobacteria-
specific antibodies in these infants decay rapidly, and that
maternal infection with M. tuberculosis is associated with
lower infant T-cell responses to BCG immunization. Confir-
mation of these results will guide the use of BCG and
newly developed vaccines in TB endemic areas.
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